Zevra Therapeutics Announces Groundbreaking MIPLYFFA™ for Niemann-Pick Disease
Zevra Therapeutics has announced the U.S. Food and Drug Administration's (FDA) approval of MIPLYFFA™ (arimoclomol) capsules as an oral treatment for Niemann-Pick disease type C (NPC).
This marks the first FDA-approved drug for NPC and is intended to be used alongside miglustat for treating neurological symptoms in patients aged two years and older. Additionally, Zevra has obtained a rare pediatric disease priority review voucher (PRV) with this approval.
NPC is a rare and progressive neurodegenerative disease affecting an estimated 900 individuals in the U.S., with around one-third diagnosed. The condition can manifest differently in both children and adults, leading to significant physical and cognitive challenges.
The approval was based on a comprehensive review of data from a 12-month clinical trial, where MIPLYFFA combined with miglustat demonstrated the ability to halt disease progression. Results showed a decrease in disease severity compared to patients receiving miglustat alone. The drug is taken orally three times a day, with dosages tailored to the patient's weight.
Zevra plans to launch MIPLYFFA in the U.S. To support patients and their families, it also introduced AmplifyAssist™, a patient support programme offering assistance with insurance coverage, copay identification, and therapy management.
